Alnylam Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alnylam Pharmaceuticals Inc.
Alnylam pushed back the study’s top-line readout to June or July. But analysts said the changes increase the odds of demonstrating monotherapy benefit with Amvuttra in ATTR-CM.
After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration.
Scrip spoke with Roche Pharmaceuticals CEO Teresa Graham about efforts to boost product sales, build out the drug development portfolio and return the company to revenue growth.
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Regulus Therapeutics, Inc.
- Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.